Rankings
▼
Calendar
KYMR (Kymera Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
KYMR
Kymera Therapeutics, Inc.
Mkt Cap
$7B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$39M
Net Income (TTM)
-$311M
EPS (TTM)
-$3.69
Free Cash Flow (TTM)
-$234M
Gross Margin
100.0%
Op. Margin
-891.3%
Net Margin
-794.4%
FCF Margin
-597.8%
P/S Ratio (TTM)
180.2x
P/E Ratio (TTM)
—
YoY Rev Growth
-16.7%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$9M
$9M
-$45M
Q2 23
$17M
$17M
-$43M
Q3 23
$5M
$5M
-$58M
Q4 23
$48M
$48M
-$19M
Q1 24
$10M
$10M
-$58M
Q2 24
$26M
$26M
-$51M
Q3 24
$4M
$4M
-$72M
Q4 24
$7M
$7M
-$81M
Q1 25
$22M
$22M
-$74M
Q2 25
$11M
$9M
-$85M
Q3 25
$3M
-$71M
-$93M
Q4 25
$3M
$79M
-$98M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
151.4x
—
Q2 23
136.7x
—
Q3 23
150.8x
—
Q4 23
89.9x
—
Q1 24
89.0x
—
Q2 24
79.8x
—
Q3 24
80.7x
—
Q4 24
150.1x
—
Q1 25
120.0x
—
Q2 25
158.0x
—
Q3 25
161.5x
—
Q4 25
180.2x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$44M
-$48M
Q2 23
-$35M
-$46M
Q3 23
-$32M
-$40M
Q4 23
$8M
-$4M
Q1 24
-$40M
-$47M
Q2 24
-$43M
-$48M
Q3 24
-$50M
-$50M
Q4 24
-$62M
-$63M
Q1 25
-$79M
-$80M
Q2 25
-$60M
-$61M
Q3 25
-$27M
-$27M
Q4 25
-$67M
-$67M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$4M
Q2 23
$11M
Q3 23
$8M
Q4 23
$12M
Q1 24
$7M
Q2 24
$5M
Q3 24
$189K
Q4 24
$936K
Q1 25
$467K
Q2 25
$695K
Q3 25
$181K
Q4 25
$106K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-1.6%
+17.7%
Q2 23
+43.4%
+14.5%
Q3 23
-50.5%
+14.3%
Q4 23
+196.7%
+22.7%
Q1 24
+8.7%
+24.3%
Q2 24
+55.3%
+27.8%
Q3 24
-20.9%
+21.9%
Q4 24
-84.6%
+31.2%
Q1 25
+114.8%
+41.7%
Q2 25
-55.3%
+25.4%
Q3 25
-26.1%
+25.6%
Q4 25
-61.3%
+14.3%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$9M
99.1%
Q2 23
$11M
67.7%
Q3 23
$12M
246.5%
Q4 23
$11M
22.8%
Q1 24
$12M
116.3%
Q2 24
$14M
55.9%
Q3 24
$15M
398.4%
Q4 24
$14M
186.6%
Q1 25
$14M
64.4%
Q2 25
$15M
134.3%
Q3 25
$16M
571.7%
Q4 25
$14M
505.3%
marketcaparena.com
OpEx Breakdown
R&D
G&A
Quarter
R&D
G&A
Q1 23
$42M
$13M
Q2 23
$46M
$14M
Q3 23
$48M
$14M
Q4 23
$53M
$14M
Q1 24
$49M
$14M
Q2 24
$59M
$17M
Q3 24
$60M
$15M
Q4 24
$72M
$16M
Q1 25
$80M
$16M
Q2 25
$78M
$18M
Q3 25
$74M
$17M
Q4 25
$84M
$17M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$50M
$347M
$397M
Q2 23
$52M
$315M
$368M
Q3 23
$81M
$277M
$358M
Q4 23
$110M
$265M
$375M
Q1 24
$94M
$427M
$521M
Q2 24
$68M
$442M
$510M
Q3 24
$111M
$439M
$550M
Q4 24
$120M
$368M
$489M
Q1 25
$90M
$373M
$463M
Q2 25
$336M
$330M
$665M
Q3 25
$113M
$393M
$506M
Q4 25
$357M
$491M
$848M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
58M
+0.5%
Q2 23
58M
+0.2%
Q3 23
58M
+0.2%
Q4 23
59M
+0.2%
Q1 24
71M
+20.9%
Q2 24
73M
+3.2%
Q3 24
76M
+4.2%
Q4 24
80M
+5.1%
Q1 25
80M
+0.2%
Q2 25
80M
+0.4%
Q3 25
87M
+8.5%
Q4 25
84M
-3.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 18
—
—
FY 19
—
—
FY 20
$454K
75
FY 21
$517K
141
FY 22
$280K
167
FY 23
$420K
187
FY 24
$250K
188
FY 25
$165K
238
marketcaparena.com